Certara announces plans to release its third-quarter 2026 financial results on November 5, 2026. The company, specializing in model-informed drug development, will disclose earnings before market open. This follows its established reporting schedule for quarterly financial updates.
Certara introduces **D360 26.5**, a software update featuring new peptide design tools, Excel integration, and usability improvements. These enhancements accelerate the transition from peptide sequence ideas to prioritized design candidates in drug discovery workflows. The platform now streamlines workflows for researchers developing peptide-based therapeutics.
Certara consolidates Chemaxon customer support into its own **Certara Service Desk**, replacing the existing Freshdesk system. The transition occurs on **October 5**, requiring users to submit support requests through the new platform. Certara highlights updated processes and submission methods for affected customers.
Certara integrates its chemical sketching tool, **Marvin**, across its Discovery portfolio, unifying workflows in **Design Hub, Compound Registration, Compliance Checker, and D360** under a single editor. The move streamlines chemical drawing processes for drug discovery teams. Marvin now serves as the central interface for structural design and validation tasks.
Certara reports a 4% increase in software revenue to **$48.8 million** and a **9% rise in software bookings** for Q2 2026, while posting a **$6.1 million net loss**—a shift from a prior-year profit. The company follows a recent divestiture with workforce reductions, balancing cost cuts against growth in its core software segment.
Certara delivers Q2 2026 earnings, highlighting revenue growth driven by its pharmaceutical solutions. The company expands its AI-driven drug development platform, Simcyp, with new partnerships in clinical pharmacology. Certara also announces progress in its oncology-focused research initiatives, leveraging computational modeling to accelerate therapeutic discovery. Leadership emphasizes scaling global operations amid rising demand for precision medicine tools.
Certara releases a Python API for Chemaxon cheminformatics tools, enabling native molecular conversion, property calculations, fingerprinting, and similarity search. Users can integrate these functionalities directly into Python workflows via pip installation.